If you have been getting compounded semaglutide from a telehealth site or med spa, you have probably noticed the ground shifting under you. Pharmacies are cutting patients off, websites are disappearing, and refill emails are going unanswered. Thousands of patients are now researching switching from compounded semaglutide to Wegovy, Zepbound, or the new oral options, and most of them are getting bad information from the same internet that sold them the compounded product in the first place.
This article walks through why the compounded supply is drying up in 2026, what a licensed provider actually assesses when mapping your current dose to a new medication, how to avoid a side-effect flare-up mid-switch, and what the real self-pay math looks like right now. It is written by the clinical team at Impact Health Clinics, a provider-led medical weight loss practice with four Mississippi locations.
Why Compounded Semaglutide Is Disappearing in 2026
Short version: the legal window that allowed mass-produced compounded semaglutide closed when the FDA declared the brand shortage resolved in early 2025, and enforcement has escalated hard since then.
Here is the 2026 timeline that matters if you are still on a compounded product:
- September 2025: the FDA sent roughly 80 warning letters and 40 untitled letters, most aimed at telehealth marketing of compounded GLP-1 products.
- March 3, 2026: the FDA announced 30 more warning letters to telehealth companies for illegally marketing compounded GLP-1s as equivalent to FDA-approved drugs.
- June 2026: during the week of June 15, the FDA issued another 25 warning letters over false or misleading claims about compounded GLP-1 products. That is three major enforcement waves in under a year.
- Safety reports: as of May 21, 2026, the FDA had logged more than 1,700 adverse event reports associated with compounded semaglutide and tirzepatide.
Some pharmacies are still operating under a claimed "personalization" exception, arguing that a slightly tweaked dose or an added ingredient like B12 makes their product a legal patient-specific compound. The FDA has made it clear it is not persuaded by that argument at scale, and companies relying on it are exactly the ones receiving letters. If your supplier is one of them, you should assume your supply could stop with little notice.
None of this means you did something wrong by taking a compounded product. It means the market that supplied it is being shut down, and you need a transition plan rather than a panic stop. Stopping a GLP-1 abruptly often means the return of appetite, regain of weight, and loss of the metabolic progress you paid for. A managed switch protects that progress.
Switching From Compounded Semaglutide to Wegovy: What Your Provider Will Assess
You will find dose-conversion charts floating around Reddit and Facebook groups. Do not use them. Here is why this is a provider decision and not a spreadsheet exercise.
1. What you were actually taking
Compounded semaglutide is not standardized. Two vials labeled the same milligram strength can differ in concentration, in salt form, and in added ingredients. Some products used semaglutide sodium or acetate salts rather than the base form found in Wegovy, which changes how much active drug you were really getting. Some included B12 or other additives. Your provider will want to see your vial label, your pharmacy paperwork, and your actual injection volume, not just the number you remember.
2. Where you land on the brand titration ladder
Wegovy comes in fixed doses: 0.25, 0.5, 1, 1.7, and 2.4 mg weekly, plus a 7.2 mg high-dose option Novo introduced for injection patients. Your compounded dose almost never matches one of those numbers exactly. The general concept your provider applies is to place you at the nearest equal or slightly lower brand dose, then reassess. Slightly lower is usually the safer direction, because overshooting is what produces the nausea and vomiting flare-ups people fear. Most established patients do not have to restart at 0.25 mg, but some do if their compounded sourcing was questionable or their dose history is unclear.
3. Whether semaglutide is still the right molecule
A forced switch is also a natural decision point. If your weight loss stalled on semaglutide, your provider may discuss tirzepatide, the dual GIP/GLP-1 agonist sold as Zepbound, which produced greater average weight loss in Eli Lilly's head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine in May 2025. If injections were the problem, the new oral option exists now too. More on both below.
4. Your labs and your history
Any responsible clinic will review recent labs before continuing therapy: metabolic panel, A1c, lipids, thyroid. At Impact Health Clinics we require labs for every patient. An in-clinic draw with our Essential Wellness Panel is $99, or if you had labs drawn elsewhere in the last six months we will review them for $25. Full details are on our pricing page.
How to Avoid a Side-Effect Flare-Up Mid-Switch
The most common transition mistake is treating the switch casually, either doubling up doses out of fear of a gap or jumping to a higher brand dose than the compounded dose actually delivered. Both cause trouble. Here is what a managed transition looks like in practice:
- Timing the first new dose. Semaglutide has a half-life of about a week. Your provider will schedule your first brand dose based on when your last compounded injection was, typically keeping the normal weekly rhythm rather than starting early or leaving a long gap.
- Matching or stepping down, not up. Because compounded concentrations are unreliable, starting at the nearest equal or lower brand dose and holding there for a few weeks is the conservative play. A dose increase can come later once you have tolerated the switch.
- Nausea management basics. Smaller meals, more protein, less fatty and fried food, steady hydration, and not lying down right after eating. If nausea does spike, your provider can hold your dose flat longer or prescribe anti-nausea support rather than pushing through.
- No stacking, no bridging with leftover vials. Combining a leftover compounded supply with a new brand pen is how people end up effectively double-dosed. Finish the plan your provider gives you and set the old vials aside.
- A check-in two to four weeks after the switch. Appetite control, side effects, and weight trend tell your provider whether the mapped dose was right or needs adjusting.
None of this is complicated, but all of it requires someone medically responsible on the other end of the phone. That is the real difference between a clinic and a checkout page.
What the Switch Costs in 2026: Real Numbers
The good news is that brand-name self-pay pricing in mid-2026 is dramatically better than it was two years ago, when Wegovy listed around $1,349 a month. Here is the current landscape. Manufacturer prices below are set by Novo Nordisk and Eli Lilly and can change, so treat them as a snapshot as of July 2026.
Wegovy injection through NovoCare Pharmacy
Novo Nordisk's direct self-pay channel currently lists Wegovy injection at $349 per month for all standard doses from 0.25 mg through 2.4 mg, and $399 per month for the 7.2 mg high dose. Novo is also running an introductory offer for patients new to NovoCare Pharmacy: $199 per month for the first two fills of starter doses, available through December 31, 2026, per NovoCare's published price guide.
Oral Wegovy, the new option
On December 22, 2025, the FDA approved the Wegovy pill, the first oral GLP-1 for chronic weight management, and it launched nationally in January 2026. Oral Wegovy cost through Novo's self-pay channel: $149 per month for the 1.5 mg starting dose, with the 4 mg dose also offered at $149 for a limited time (listed through August 31, 2026, then $199), and the highest oral doses at $299 per month. The pill is taken daily on an empty stomach, which suits some patients and annoys others. Whether an oral dose can hold the appetite control you had on your injection is exactly the kind of question a transition consult answers.
Zepbound through LillyDirect
Eli Lilly's self-pay program currently prices Zepbound single-dose vials at $299 per month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg, with the maintenance pricing tied to refilling within 45 days. For patients whose semaglutide results plateaued, this is often the more interesting conversation.
A supervised program at Impact Health Clinics
Our GLP-1 weight loss program runs $299 to $549 per month depending on medication and dose: semaglutide is $299 per month at Tier 1 (0.25 to 1 mg) and $399 at Tier 2 (1.25 to 2 mg), while tirzepatide is $349 per month at Tier 1 (1 to 5 mg) and $549 at Tier 2 (5 to 10 mg). That includes weekly in-clinic injections if you want them, an at-home option (plus $25 shipping), a provider visit with labs every six months, weekly 3D body scans, and coaching. The consult to get started is $79, and it may be waived during active promotions when you start a qualifying program.
Run the totals honestly and the manufacturer programs are sometimes cheaper on medication alone, while a clinic program bundles the oversight, injections, monitoring, and accountability that most patients transitioning off compounded products say they were missing. There is no single right answer, which is why our providers will lay out both paths at your consult, including sending you toward NovoCare or LillyDirect if that genuinely fits you better. We are self-pay with no insurance billing, so the number we quote is the number you pay.
What a Transition Consult Looks Like Here
The process is simple and usually takes one visit plus labs:
- Book a $79 consult at any location or by telehealth, available five days a week for eligible Mississippi patients. Bring your compounded vial or pharmacy label and your dose history.
- Labs: $99 for an in-clinic draw, or $25 for a provider review of outside labs drawn within the last six months.
- Get a written plan: which medication, which dose, when to take the first new dose relative to your last compounded injection, and when we recheck.
- Follow-up: a check-in after the switch, then the standard visit-plus-labs cadence every six months.
We see patients in Oxford, Corinth, Olive Branch, and now Tupelo. Our new Tupelo clinic at 2604 W. Main St, Suite F holds its grand opening on Thursday, July 9, 2026, with hours on Thursdays and Fridays from 9 to 5. If you are in northeast Mississippi and your compounded supplier just went dark, the timing works out.
Frequently Asked Questions
Can I switch at the same milligram dose I was taking?
Sometimes, but not automatically. Compounded products vary in concentration and formulation, so the milligrams on your vial may not equal the milligrams a Wegovy pen delivers. Your provider will usually place you at the nearest equal or slightly lower brand dose and adjust from there. This is the core reason switching from compounded semaglutide to Wegovy should run through a provider rather than a conversion chart.
Do I have to restart at the lowest dose?
Usually not, if you have a clear, recent dose history and you tolerated your compounded dose well. Patients with unreliable sourcing, long gaps in treatment, or unclear records may be restarted lower for safety. Expect a conservative call, because the cost of overshooting is weeks of nausea.
Is compounded semaglutide still legal at all in 2026?
Narrow exceptions remain. A state-licensed 503A pharmacy can compound for a specific patient when a prescriber documents a genuine clinical need, such as an allergy to an inactive ingredient. What is no longer permitted is the mass-produced, marketed-online version most patients were actually buying, and the FDA's 2025 and 2026 warning-letter waves have been aimed squarely at that market.
How much does oral Wegovy cost right now?
Through Novo's self-pay channel as of July 2026: $149 per month for the 1.5 mg starting dose, $149 for the 4 mg dose during the current limited-time offer (then $199), and $299 per month for the highest oral doses. Prices are set by Novo Nordisk and can change.
My telehealth company shut down and I have a few doses left. What should I do?
Do not stretch, split, or stockpile doses on your own, and do not buy replacement product from gray-market sources, which is where most of the FDA's 1,700-plus adverse event reports come from. Book a consult before your supply runs out so your first brand dose can be timed off your last compounded one. If you are already out, that is fine too, we plan the restart accordingly.
The Bottom Line
The compounded semaglutide era is ending, but your progress does not have to end with it. A compounded semaglutide alternative exists at nearly every price point in 2026: brand Wegovy injection at $349 per month self-pay, oral Wegovy from $149, Zepbound from $299, or a fully supervised clinic program from $299 per month. The transition itself is the risky part, and it is only risky if nobody is managing it.
Book a $79 transition consult at our Oxford, Corinth, Olive Branch, or new Tupelo clinic, or ask about telehealth. Bring your vial, bring your questions, and leave with a written plan.
This article is for educational purposes only and is not medical advice. Treatment decisions should always be made with a licensed healthcare provider who has reviewed your labs and medical history. Contact Impact Health Clinics to schedule a consultation.